RedHill Biopharma

December 15, 2016December 15, 2016

Clinical Trial of RedHill’s Potential Crohn’s Disease Therapy Set to Continue as Planned

News

RedHill Biopharma Ltd. An Israeli biopharmaceutical company announced that an independent Data and Safety Monitoring Board (DSMB) recommended their MAP US study to continue as planned without any modifications.

June 27, 2016June 27, 2016

MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential

News

RedHill Biopharma announced the publication of a peer-review article demonstrating the potential efficacy of RHB-104 for the treatment of Mycobacterium avium subspecies paratuberculosis (MAP) infection-associated Crohn’s disease. The article was authored by researchers ... Read more

February 11, 2016February 12, 2016

RedHill Biopharma’s Potential Crohn’s Treatment, RHB-104, Likely to Receive US Patent

Crohn's Disease, IBD News, News

RedHill Biopharma recently announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent covering RHB-104, a new oral combination drug currently being assessed in clinical ... Read more

August 28, 2015August 28, 2015

RedHill Biopharma Issued Notice of Allowance for New Israeli Patent Covering RHB-104

News

Israel-based biopharmaceutical company RedHill Biopharma Ltd., announced it has been issued a Notice of Allowance by the Israeli Patent Office for a new patent (No. 207420 – “Methods and Compositions for ... Read more

August 17, 2015August 17, 2015

RedHill Biopharma Presents Crohn’s Disease Therapeutics Program at International Research Symposium

Crohn's Disease, News

Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently presented its RHB-104 Phase III Crohn’s disease program at the International Research Symposium for Game Changing Concepts in Crohn’s Medicine on Sunday, August 16, 2015 ... Read more

July 7, 2015July 7, 2015

RedHill Biopharma Authorized to Test RHB-104 for Crohn’s Disease in Australia and New Zealand

Crohn's Disease, News

Israel-based RedHill Biopharma Ltd. recently disclosed it has been granted authorization to begin enrolling patients in Australia and New Zealand for a Phase III clinical trial designed to test RHB-104 as a ... Read more

July 2, 2015July 2, 2015

RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate

Crohn's Disease, News

Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently announced its acquisition of two notices of allowance from the United States Patent and Trademark Office (USPTO) covering patient application numbers 13/722,395 and 14/271,758 for RHB-104, ... Read more

June 17, 2015September 28, 2016

RedHill Announces MHRA Acceptance of Clinical Trial Application for Phase III clinical trial of RHB-104 in Crohn’s Disease

Crohn's Disease, News

RedHill Biopharma Ltd., an emerging biopharmaceutical company based in Israel focused on the development of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, recently announced that the UK ... Read more

June 4, 2015September 28, 2016

RedHill Releases Update on Promising IBD Therapies

IBD News, News

Israel-based biopharmaceutical company RedHill Biopharma recently released an update on the development of its drug pipeline, including a treatment for Crohn’s disease, and announced key milestones expected by the company for the upcoming period. RedHill ... Read more

May 28, 2015May 28, 2015

RedHill to Present Crohn’s Therapy at Upcoming Conference

Crohn's Disease, News

RedHill Biopharma recently announced in a press release that the company will be hosting a presentation at the upcoming Jefferies 2015 Global Healthcare Conference. Guy Goldberg, RedHill’s chief business officer, will discuss RedHill’s progress in developing late clinical-stage, ... Read more